HSPBAP1
gene geneOn this page
Also known as FLJ22623PASS1
Summary
HSPBAP1 (HSPB1 associated protein 1, HGNC:16389) is a protein-coding gene on chromosome 3q21.1, encoding HSPB1-associated protein 1 (Q96EW2). May play a role in cellular stress response.
This gene encodes a protein that binds to one of the small heat shock proteins, specifically hsp27. Hsp27 is involved with cell growth and differentiation. This encoded protein was found to be abnormally expressed in patients with intractable epilepsy, although how brain function is affected remains unknown.
Source: NCBI Gene 79663 — RefSeq curated summary.
At a glance
- Clinical variants (ClinVar): 77 total
- MANE Select transcript:
NM_024610
Identifiers
Gene identifiers
| Field | Value |
|---|---|
| HGNC ID | HGNC:16389 |
| Approved symbol | HSPBAP1 |
| Name | HSPB1 associated protein 1 |
| Location | 3q21.1 |
| Locus type | gene with protein product |
| Status | Approved |
| Aliases | FLJ22623, PASS1 |
| Ensembl gene | ENSG00000169087 |
| Ensembl biotype | protein_coding |
| OMIM | 608263 |
| Entrez | 79663 |
Gene structure
Transcript identifiers
Ensembl transcripts: 15 — 10 protein_coding, 5 protein_coding_CDS_not_defined
ENST00000306103, ENST00000463266, ENST00000465044, ENST00000467643, ENST00000471534, ENST00000478601, ENST00000877414, ENST00000877415, ENST00000877416, ENST00000877417, ENST00000936099, ENST00000936100, ENST00000936101, ENST00000936102, ENST00000971052
RefSeq mRNA: 2 — MANE Select: NM_024610
NM_001320728, NM_024610
CCDS: CCDS3017
Canonical transcript exons
ENST00000306103 — 8 exons
| Exon | Start | End |
|---|---|---|
| ENSE00001817071 | 122793617 | 122793831 |
| ENSE00003513857 | 122755260 | 122755431 |
| ENSE00003517108 | 122759224 | 122759360 |
| ENSE00003586856 | 122777721 | 122777906 |
| ENSE00003621091 | 122741003 | 122741113 |
| ENSE00003632554 | 122739999 | 122740875 |
| ENSE00003665516 | 122752591 | 122752674 |
| ENSE00003693783 | 122768701 | 122768882 |
Expression profiles
Bgee: expression breadth ubiquitous, 275 present calls, max score 95.19.
FANTOM5 (CAGE): breadth ubiquitous, TPM avg 6.8769 / max 146.2397, expressed in 1666 samples.
FANTOM5 promoters (3 alternative TSS)
| Promoter ID | TPM avg | Samples expressed |
|---|---|---|
| 44147 | 5.5327 | 1620 |
| 44146 | 1.1593 | 596 |
| 44148 | 0.1848 | 87 |
Top tissues by expression
288 total, by Bgee expression score (0-100, higher = more expressed):
| Tissue | Anatomy ID | Expression score | Quality |
|---|---|---|---|
| oocyte | CL:0000023 | 95.19 | gold quality |
| secondary oocyte | CL:0000655 | 93.13 | gold quality |
| granulocyte | CL:0000094 | 90.47 | gold quality |
| blood | UBERON:0000178 | 90.33 | gold quality |
| gastrocnemius | UBERON:0001388 | 88.86 | gold quality |
| hindlimb stylopod muscle | UBERON:0004252 | 88.63 | gold quality |
| monocyte | CL:0000576 | 88.61 | gold quality |
| mononuclear cell | CL:0000842 | 88.55 | gold quality |
| leukocyte | CL:0000738 | 88.46 | gold quality |
| spleen | UBERON:0002106 | 88.34 | gold quality |
| muscle of leg | UBERON:0001383 | 88.17 | gold quality |
| endothelial cell | CL:0000115 | 87.35 | gold quality |
| mucosa of stomach | UBERON:0001199 | 86.32 | gold quality |
| skeletal muscle organ | UBERON:0014892 | 85.36 | gold quality |
| muscle organ | UBERON:0001630 | 85.35 | gold quality |
| skin of abdomen | UBERON:0001416 | 85.26 | gold quality |
| skin of leg | UBERON:0001511 | 85.08 | gold quality |
| left lobe of thyroid gland | UBERON:0001120 | 84.94 | gold quality |
| primordial germ cell in gonad | CL:0000670 ∩ UBERON:0000991 | 84.91 | gold quality |
| right lobe of thyroid gland | UBERON:0001119 | 84.76 | gold quality |
| metanephros cortex | UBERON:0010533 | 84.46 | gold quality |
| thyroid gland | UBERON:0002046 | 84.28 | gold quality |
| right lung | UBERON:0002167 | 84.09 | gold quality |
| male germ line stem cell (sensu Vertebrata) in testis | CL:0000089 ∩ UBERON:0000473 | 84.00 | gold quality |
| skin of hip | UBERON:0001554 | 83.89 | gold quality |
| placenta | UBERON:0001987 | 83.73 | gold quality |
| left adrenal gland cortex | UBERON:0035825 | 83.59 | gold quality |
| right adrenal gland cortex | UBERON:0035827 | 83.47 | gold quality |
| right adrenal gland | UBERON:0001233 | 83.29 | gold quality |
| small intestine Peyer’s patch | UBERON:0003454 | 83.28 | gold quality |
Single-cell (SCXA)
Detected in 1 experiment(s), a significant marker in 0.
| Experiment | Marker? | Max mean expression |
|---|---|---|
| E-ANND-3 | no | 4.78 |
Regulation
Is transcription factor: no
miRNA regulators (miRDB)
35 targeting HSPBAP1, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):
| miRNA | Max score | Avg score | miRNA target_count |
|---|---|---|---|
| HSA-MIR-1277-5P | 100.00 | 73.95 | 5056 |
| HSA-MIR-4795-3P | 100.00 | 74.62 | 4024 |
| HSA-MIR-5011-5P | 100.00 | 83.46 | 5820 |
| HSA-MIR-190A-3P | 100.00 | 80.35 | 5520 |
| HSA-MIR-4282 | 99.99 | 75.36 | 6408 |
| HSA-MIR-548AW | 99.99 | 72.57 | 3559 |
| HSA-MIR-548N | 99.98 | 71.94 | 4170 |
| HSA-MIR-19A-3P | 99.98 | 75.33 | 2762 |
| HSA-MIR-19B-3P | 99.98 | 75.44 | 2754 |
| HSA-MIR-450B-5P | 99.92 | 71.48 | 3175 |
| HSA-MIR-548AJ-5P | 99.78 | 71.12 | 3085 |
| HSA-MIR-548F-5P | 99.78 | 71.02 | 3093 |
| HSA-MIR-548G-5P | 99.78 | 71.12 | 3085 |
| HSA-MIR-548X-5P | 99.78 | 71.12 | 3085 |
| HSA-MIR-1255A | 99.74 | 68.09 | 744 |
| HSA-MIR-1255B-5P | 99.74 | 68.16 | 741 |
| HSA-MIR-3125 | 99.14 | 68.49 | 2269 |
| HSA-MIR-485-5P | 99.10 | 64.78 | 1889 |
| HSA-MIR-6884-5P | 99.10 | 64.50 | 1987 |
| HSA-MIR-628-3P | 99.04 | 68.37 | 814 |
| HSA-MIR-3916 | 98.99 | 68.04 | 2155 |
| HSA-MIR-3926 | 98.95 | 69.26 | 1438 |
| HSA-MIR-5187-5P | 98.54 | 67.94 | 952 |
| HSA-MIR-548S | 98.50 | 67.17 | 1213 |
| HSA-MIR-12126 | 98.09 | 64.82 | 637 |
| HSA-MIR-4494 | 97.86 | 64.93 | 850 |
| HSA-MIR-6893-3P | 97.79 | 64.91 | 1238 |
| HSA-MIR-3928-3P | 97.61 | 66.53 | 1096 |
| HSA-MIR-370-3P | 97.09 | 64.92 | 1221 |
| HSA-MIR-514A-3P | 96.43 | 67.77 | 1048 |
Literature-anchored findings (GeneRIF, showing 3)
- Molecular cloning and characterization of a novel human gene (HSPBAP1) from human fetal brain (PMID:11978969)
- HSPBAP1 is found extensively in the anterior temporal neocortex of patients with intractable epilepsy. (PMID:17568411)
- Data suggest a novel role and a possible link for HSPBAP1 in promoting prostate cancer cell survival in androgen-deficient conditions by maintaining a basal level of androgen receptor-mediated transcription. (PMID:25359680)
Cross-species orthologs
4 orthologs
| Organism | Symbol | Gene ID |
|---|---|---|
| danio_rerio | hspbap1 | ENSDARG00000033771 |
| mus_musculus | Hspbap1 | ENSMUSG00000022849 |
| rattus_norvegicus | Hspbap1 | ENSRNOG00000002241 |
| drosophila_melanogaster | HSPBAP1 | FBGN0263025 |
Paralogs (4): KDM8 (ENSG00000155666), TYW5 (ENSG00000162971), HIF1AN (ENSG00000166135), JMJD7 (ENSG00000243789)
Protein
Protein identifiers
HSPB1-associated protein 1 — Q96EW2 (reviewed: Q96EW2)
Alternative names: 27 kDa heat shock protein-associated protein 1, Protein associated with small stress protein 1
All UniProt accessions (1): Q96EW2
UniProt curated annotations — full annotation on UniProt →
Function. May play a role in cellular stress response.
Subunit / interactions. Interacts with CRYAB and HSPB1.
Subcellular location. Cytoplasm.
Tissue specificity. Widely expressed.
Disease relevance. A chromosomal aberration involving HSPBAP1 has been found in a family with renal carcinoma. Translocation t(2;3)(q35;q21) with the putative pseudogene DIRC3. Produces a hybrid mRNA encoding a truncated HSPBAP1 lacking the first 36 amino acids.
Isoforms (3)
| UniProt ID | Names | Canonical? |
|---|---|---|
| Q96EW2-1 | 1 | yes |
| Q96EW2-2 | 2 | |
| Q96EW2-3 | 3 |
RefSeq proteins (2): NP_001307657, NP_078886* (*=MANE)
Domains & families (InterPro)
| ID | Name | Type |
|---|---|---|
| IPR003347 | JmjC_dom | Domain |
| IPR013296 | HSPB1-associated_protein_1 | Family |
| IPR041667 | Cupin_8 | Domain |
Pfam: PF13621
UniProt features (13 total): splice variant 4, sequence conflict 3, region of interest 2, chain 1, domain 1, compositionally biased region 1, sequence variant 1
Structure
Experimental structures (PDB)
0 structures.
Predicted structure (AlphaFold)
| Model | pLDDT | Fraction very-high |
|---|---|---|
| AF-Q96EW2-F1 | 79.79 | 0.64 |
Function
Pathways and Gene Ontology
Reactome pathways
0 pathways
MSigDB gene sets: 131 (showing top):
GOMF_OXIDOREDUCTASE_ACTIVITY_ACTING_ON_PAIRED_DONORS_WITH_INCORPORATION_OR_REDUCTION_OF_MOLECULAR_OXYGEN, IVANOVA_HEMATOPOIESIS_LATE_PROGENITOR, USF_C, MYCMAX_01, BLALOCK_ALZHEIMERS_DISEASE_UP, USF_01, LIAO_METASTASIS, LIAO_HAVE_SOX4_BINDING_SITES, chr3q21, MARSON_BOUND_BY_FOXP3_STIMULATED, SANSOM_APC_TARGETS, SANSOM_APC_MYC_TARGETS, SANSOM_APC_TARGETS_REQUIRE_MYC, GEORGES_TARGETS_OF_MIR192_AND_MIR215, GOMF_DIOXYGENASE_ACTIVITY
GO Biological Process (0):
GO Molecular Function (2): 2-oxoglutarate-dependent dioxygenase activity (GO:0016706), protein binding (GO:0005515)
GO Cellular Component (1): cytoplasm (GO:0005737)
GO top-level categories
Rollup of top GO terms by namespace:
| Category | Terms |
|---|---|
| oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen | 1 |
| dioxygenase activity | 1 |
| binding | 1 |
| intracellular anatomical structure | 1 |
| cellular anatomical structure | 1 |
Protein interactions and networks
STRING
618 interactions, top by confidence (×1000):
| Protein A | Protein B | Partner UniProt | Score |
|---|---|---|---|
| HSPBAP1 | HSPB2 | Q16082 | 882 |
| HSPBAP1 | HSPB1 | P04792 | 873 |
| HSPBAP1 | HSPB3 | Q12988 | 856 |
| HSPBAP1 | SLC49A4 | Q96SL1 | 732 |
| HSPBAP1 | JMJD4 | Q9H9V9 | 707 |
| HSPBAP1 | RIOX1 | Q9H6W3 | 681 |
| HSPBAP1 | DIRC1 | Q969H9 | 638 |
| HSPBAP1 | LRIG1 | Q96JA1 | 588 |
| HSPBAP1 | RIOX2 | Q8IUF8 | 560 |
| HSPBAP1 | PPP1R36 | Q96LQ0 | 503 |
| HSPBAP1 | C9K0I3 | C9K0I3 | 502 |
| HSPBAP1 | JMJD6 | Q6NYC1 | 501 |
| HSPBAP1 | PTPRG | P23470 | 494 |
| HSPBAP1 | RNF139 | Q8WU17 | 490 |
| HSPBAP1 | RBM46 | Q8TBY0 | 470 |
IntAct
29 interactions, top by confidence:
| A | B | Type | Score |
|---|---|---|---|
| HSPBAP1 | ARHGEF5 | psi-mi:“MI:0915”(physical association) | 0.720 |
| ARHGEF5 | HSPBAP1 | psi-mi:“MI:0915”(physical association) | 0.720 |
| XAF1 | AKT1 | psi-mi:“MI:0914”(association) | 0.670 |
| HSPBAP1 | NCALD | psi-mi:“MI:0915”(physical association) | 0.590 |
| NUTM1 | HSPBAP1 | psi-mi:“MI:0915”(physical association) | 0.560 |
| HSPBAP1 | NUTM1 | psi-mi:“MI:0915”(physical association) | 0.560 |
| MAGEA1 | MAGEB3 | psi-mi:“MI:0914”(association) | 0.530 |
| SDE2 | HSPBAP1 | psi-mi:“MI:0915”(physical association) | 0.500 |
| HSPBAP1 | ABHD10 | psi-mi:“MI:0915”(physical association) | 0.500 |
| HSPB1 | HSPBAP1 | psi-mi:“MI:0915”(physical association) | 0.400 |
| HSPBAP1 | TK1 | psi-mi:“MI:0915”(physical association) | 0.370 |
| MAGEA1 | ANKHD1 | psi-mi:“MI:0914”(association) | 0.350 |
| FOXD4L6 | ANKRD28 | psi-mi:“MI:0914”(association) | 0.350 |
| HSPBAP1 | SERPINC1 | psi-mi:“MI:0914”(association) | 0.350 |
| KRR1 | LGALS7 | psi-mi:“MI:0914”(association) | 0.350 |
| SDE2 | HOXB6 | psi-mi:“MI:0914”(association) | 0.350 |
| ABHD10 | VWA8 | psi-mi:“MI:0914”(association) | 0.350 |
| IMPDH1 | MGST3 | psi-mi:“MI:0914”(association) | 0.350 |
| MAGEA1 | ANKRD17 | psi-mi:“MI:0914”(association) | 0.350 |
| ARHGEF5 | HSPBAP1 | psi-mi:“MI:0915”(physical association) | 0.000 |
| HSPBAP1 | PTN | psi-mi:“MI:0915”(physical association) | 0.000 |
BioGRID (27): HSPBAP1 (Two-hybrid), NUTM1 (Two-hybrid), HSPBAP1 (Affinity Capture-MS), HSPBAP1 (Affinity Capture-MS), HSPBAP1 (Affinity Capture-MS), HSPBAP1 (Affinity Capture-MS), NCALD (Affinity Capture-MS), HSPBAP1 (Affinity Capture-MS), HSPBAP1 (Reconstituted Complex), PTN (Two-hybrid), HSPBAP1 (Two-hybrid), HSPBAP1 (Affinity Capture-MS), HOXA5 (Affinity Capture-MS), HSPBAP1 (Affinity Capture-MS), RPS29 (Affinity Capture-MS)
ESM2 similar proteins: A1L3L1, A2RT67, A3KPW7, A4IIA7, A8C750, A8C752, D2HNY3, E1BGQ2, E1C3P4, Q08CL8, Q08DZ8, Q0IHB3, Q149N8, Q1RMU2, Q1RMZ1, Q3MJ13, Q3T1H6, Q5F3F2, Q5RED8, Q5VVJ2, Q5ZJ87, Q66J91, Q69Z66, Q6AYF5, Q6DE97, Q6GR37, Q6P1E7, Q6PNC0, Q6YHU6, Q7TPQ3, Q8BKW4, Q8BXK4, Q8IWR0, Q8IYF3, Q8IZE3, Q8K2I9, Q8NA31, Q8NEN0, Q8NFZ0, Q96EW2
Diamond homologs: A2RSX7, A2RUC4, A8E534, B5XF11, E1C7T6, F4K2M8, Q08BV2, Q2U6D4, Q4IER0, Q4WVD1, Q54LV7, Q58CU3, Q5BH52, Q67ZB6, Q6C3P4, Q96EW2, Q9P3K9, Q5UQY3, Q6AXL5, Q8BK58, B2GUS6, P59723, Q0WVR4, Q1JP61, Q497B8, Q54FG7, Q55DF5, Q5BKC6, Q8BLR9, Q8N371, Q9CXT6, Q9NWT6, O94606, Q3TA59, Q6AY40, Q8RWR1, Q9W0M3, Q9H9V9, Q54FM1, Q96S16
SIGNOR signaling
0 interactions.
Disease & clinical
Clinical variants and AI predictions
ClinVar
77 variants total. Per-class counts are floors (≥ shown; pagination cap):
| Classification | Count (floor) |
|---|---|
| Pathogenic | 0 |
| Likely pathogenic | 0 |
| Uncertain significance | 56 |
| Likely benign | 6 |
| Benign | 0 |
Top pathogenic / likely-pathogenic (0)
SpliceAI
1678 predictions. Top by Δscore:
| Variant | Effect | Δscore |
|---|---|---|
| 3:122740872:CAAC:C | acceptor_gain | 1.0000 |
| 3:122740875:CCTAA:C | acceptor_loss | 1.0000 |
| 3:122740876:CTAA:C | acceptor_loss | 1.0000 |
| 3:122740877:T:C | acceptor_loss | 1.0000 |
| 3:122740999:CTAC:C | donor_loss | 1.0000 |
| 3:122741000:TACC:T | donor_loss | 1.0000 |
| 3:122741001:ACC:A | donor_loss | 1.0000 |
| 3:122741002:C:A | donor_loss | 1.0000 |
| 3:122768696:CTTA:C | donor_loss | 1.0000 |
| 3:122768697:TTAC:T | donor_loss | 1.0000 |
| 3:122768699:ACCTG:A | donor_loss | 1.0000 |
| 3:122768700:C:CA | donor_loss | 1.0000 |
| 3:122768883:C:CC | acceptor_gain | 1.0000 |
| 3:122777757:T:C | donor_gain | 1.0000 |
| 3:122777906:CCTAG:C | acceptor_loss | 1.0000 |
| 3:122777907:C:CC | acceptor_gain | 1.0000 |
| 3:122777907:CTA:C | acceptor_loss | 1.0000 |
| 3:122777908:T:C | acceptor_loss | 1.0000 |
| 3:122740876:C:CC | acceptor_gain | 0.9900 |
| 3:122741110:CTTC:C | acceptor_gain | 0.9900 |
| 3:122741114:C:CC | acceptor_gain | 0.9900 |
| 3:122741115:T:A | acceptor_loss | 0.9900 |
| 3:122755432:C:CC | acceptor_gain | 0.9900 |
| 3:122755436:T:TC | acceptor_gain | 0.9900 |
| 3:122759226:T:A | donor_gain | 0.9900 |
| 3:122768879:GGAA:G | acceptor_gain | 0.9900 |
| 3:122768880:GAA:G | acceptor_gain | 0.9900 |
| 3:122768880:GAAC:G | acceptor_loss | 0.9900 |
| 3:122768881:AA:A | acceptor_gain | 0.9900 |
| 3:122768883:CT:C | acceptor_loss | 0.9900 |
AlphaMissense
3246 scored. Top likely-pathogenic:
| Variant | Protein change | am_pathogenicity |
|---|---|---|
| 3:122752602:A:G | W272R | 0.999 |
| 3:122752602:A:T | W272R | 0.999 |
| 3:122755424:A:G | W193R | 0.999 |
| 3:122755424:A:T | W193R | 0.999 |
| 3:122759303:A:G | W164R | 0.999 |
| 3:122759303:A:T | W164R | 0.999 |
| 3:122759351:A:G | W148R | 0.999 |
| 3:122759351:A:T | W148R | 0.999 |
| 3:122752612:A:C | S268R | 0.998 |
| 3:122752612:A:T | S268R | 0.998 |
| 3:122752614:T:G | S268R | 0.998 |
| 3:122752664:A:T | V251D | 0.998 |
| 3:122755347:A:C | S218R | 0.998 |
| 3:122755347:A:T | S218R | 0.998 |
| 3:122755349:T:G | S218R | 0.998 |
| 3:122759270:G:C | H175D | 0.998 |
| 3:122752600:C:A | W272C | 0.997 |
| 3:122752600:C:G | W272C | 0.997 |
| 3:122752647:G:C | H257D | 0.997 |
| 3:122752650:A:G | W256R | 0.997 |
| 3:122752650:A:T | W256R | 0.997 |
| 3:122755356:A:C | S215R | 0.997 |
| 3:122755356:A:T | S215R | 0.997 |
| 3:122755358:T:G | S215R | 0.997 |
| 3:122755428:T:A | K191N | 0.997 |
| 3:122755428:T:G | K191N | 0.997 |
| 3:122752606:G:C | N270K | 0.996 |
| 3:122752606:G:T | N270K | 0.996 |
| 3:122755350:G:C | F217L | 0.996 |
| 3:122755350:G:T | F217L | 0.996 |
dbSNP variants (sampled 300 via entrez): RS1000027824 (3:122743820 G>A), RS1000115234 (3:122768440 C>A), RS1000121196 (3:122763876 C>T), RS1000272972 (3:122787266 G>A), RS1000299953 (3:122753992 G>C), RS1000415567 (3:122753596 T>C), RS1000578592 (3:122766241 T>A), RS1000621934 (3:122747999 A>T), RS1000733263 (3:122747909 T>C,G), RS1000756700 (3:122755574 T>C), RS1000835496 (3:122782278 A>C,T), RS1000888401 (3:122771680 C>G), RS1000901829 (3:122751613 T>C), RS1001048348 (3:122789460 C>T), RS1001070846 (3:122758279 C>T)
Disease associations
OMIM: gene MIM:608263 | disease phenotypes:
GenCC curated gene-disease
Mondo (0):
Orphanet (0):
HPO phenotypes
0 total (0 of 0 shown, HPO-id order):
GWAS associations
0 associations (top):
Drugs & pharmacology
Drug and pharmacology data
Is drug target: no
PharmGKB: 1 entry (VIP=true, CPIC=false)
CTD chemical–gene interactions
42 total (human), top 30 by PubMed support.
| Chemical | Actions (top 5) | PubMed papers |
|---|---|---|
| Cyclosporine | increases expression | 4 |
| Valproic Acid | affects expression, decreases expression, increases expression | 3 |
| bisphenol A | affects methylation | 2 |
| sodium arsenite | affects cotreatment, decreases expression, increases abundance, increases expression | 2 |
| aminomethylphosphonic acid (AMPA) | increases expression | 1 |
| triphenyl phosphate | affects expression | 1 |
| arsenite | affects binding, increases reaction | 1 |
| tris(1,3-dichloro-2-propyl)phosphate | increases expression | 1 |
| cypermethrin | increases expression | 1 |
| manganese chloride | increases abundance, affects cotreatment, decreases expression | 1 |
| di-n-butylphosphoric acid | affects expression | 1 |
| perfluorooctane sulfonic acid | increases expression | 1 |
| pentabromodiphenyl ether | increases expression | 1 |
| perfluoro-n-nonanoic acid | increases expression | 1 |
| abrine | increases expression | 1 |
| 2,2’,4,4’-tetrabromodiphenyl ether | increases expression | 1 |
| NSC 689534 | affects binding, increases expression | 1 |
| 2,3,5-trichloro-6-phenyl-(1,4)benzoquinone | decreases expression | 1 |
| Resveratrol | affects cotreatment, increases expression | 1 |
| Decitabine | affects expression | 1 |
| Sunitinib | increases expression | 1 |
| Acetaminophen | increases expression | 1 |
| Glyphosate | increases expression | 1 |
| Air Pollutants | affects expression, increases abundance | 1 |
| Arsenic | affects cotreatment, decreases expression, increases abundance | 1 |
| Atrazine | decreases expression | 1 |
| Benzo(a)pyrene | increases expression | 1 |
| Cisplatin | affects expression | 1 |
| Copper | affects binding, increases expression | 1 |
| Doxorubicin | decreases expression | 1 |
Clinical trials (associated diseases)
0 trials via MONDO — disease-level, not drug-specific.
Related Atlas pages
No linked Atlas pages yet — the cross-entity mesh grows as the corpus expands.